Value202020212022202320242025TTMSelling/general/admin expenses2.69 B3.08 B3.07 B3.21 B3.25 B3.45 B—Research & development673 M842 M702 M828 M876 M990 M—Operating income482 M580 M672 M1.04 B1.41 B1.36 B—Non-Operating Income, Total———————Interest expense, net of interest capitalized———————Non-Operating Income, excl. Interest Expenses———————Unusual income/expense———————Pretax income635 M418 M463 M832 M1.26 B1.16 B—Equity in earnings———————Taxes104 M42 M128 M142 M238 M180 M—Non-controlling/minority interest—————0—After tax other income/expense———————Net income before discontinued operations531 M376 M335 M974 M1.02 B980 M—Discontinued operations———————Net income531 M376 M335 M974 M1.02 B980 M—Dilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders———————Basic earnings per share (Basic EPS)———————Diluted earnings per share (Diluted EPS)———————Average basic shares outstanding———————Diluted shares outstanding———————EBITDA———————EBIT———————Cost of revenue3.83 B3.58 B3.91 B4.14 B4.33 B4.59 B—Other cost of goods sold———————Depreciation & amortization (cash flow)———————
Alcon Inc
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.